摘要
目的 研究AKT2蛋白产物在原发性肝癌发生、发展过程中的表达特点。方法 应用免疫组化SP法和RT-PCR法检测32例原发性肝癌中AKT2的表达，并以同期4例良性肝脏疾病作为对照。结果 原发性肝癌的AKT2基因蛋白产物阳性表达率（62．5％，28／32）显著高于良性对照组（O，O／4）。AKT2在低分化、有淋巴结或远处转移组的表达率明显高于高中分化、无转移组。AKT2术后随访显示阳性肝癌患者的中位生存时间显著低于AKT2阴性患者（76dLL463d）。结论 在原发性肝癌中AKT2表达上调。AKT2在肝癌的发生、发展、转移中起重要作用。检测AKT2在原发性肝癌中的表达有助于反映原发性肝癌的生物学特性，为预后判断提供参考指标，并为干预性基因治疗提供实验依据。
Objective To study the expression of AKT2 gene in liver cancer and its relationship to tumor progression. Methods The expression of AKT2 in liver cancer was detected by SP immuno- histochemical stainin and reverse transcription polymerase chain reaction （RT-PCR）. Four patients with benign liver tumors were used as control. Results The positive rates of AKT2 in liver cancer tissue and benign control tissue were 62.5% （28/32） and 0% （0/4）, respectively. The difference was significant. In addition, a positive expression of AKT2 correlated significantly with poor differentiation, positive lymph node and distant metastasis. The median survival after surgery was significantly shorter in patients with positive than with negative AKT2 （76d vs 463d）. Conclusion The detection of AKT2 was useful in assessing the progression of liver cancer, in determining prognosis and eventu- ally in rendering a possible target for novel therapeutic strategies.
出处
《中华肝胆外科杂志》
CAS
CSCD
北大核心
2012年第1期34-36,共3页
Chinese Journal of Hepatobiliary Surgery
